Quantcast
Last updated on April 19, 2014 at 7:22 EDT

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

April 6, 2009

NEW YORK, April 6 /PRNewswire/ — Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. (NYSE Amex: CUR). The full 56-page report can be found at www.crystalra.com.

Neuralstem, Inc. (“Neuralstem” or “the Company”) is a biotherapeutics company using a patented process to grow neural stem cells to treat central nervous system (CNS) diseases. The neurodegenerative conditions that the Company targets are incurable and are usually associated with severe side effects, such as muscle atrophy, partial or complete paralysis, or death. Neuralstem’s proprietary Human Neural Stem Cell technology isolates stem cells from CNS tissue of the developing human brain and spinal cord and expands these cells in the laboratory for up to 60 doublings. By amplifying the natural ability of fetal stem cells to self-renew for long time periods, the Company creates billions of cells from each original stem cell–enabling commercial quantities from a sole donated tissue. To Neuralstem’s knowledge, its technology was the first to accomplish both commercial quantities and controlled differentiation of neural stem cells into mature, physiologically relevant neurons and glia.

The initial product candidate of this therapeutic platform is a spinal cord cell line. When implanted into animal models, the cells have extended the lives of rats with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and reversed paralysis in ischemic spastic paraplegia models. In December 2008, Neuralstem filed an Investigational New Drug (IND) application for a Phase I trial of its spinal cord cells in patients with ALS, which affects roughly 30,000 people in the U.S. In February 2009, the Company received the FDA’s response, which Neuralstem is now addressing. In a Phase I trial, the Company aims to study the safety and feasibility of injecting its cells directly into the spinal cords of ALS patients, where the healthy, fully functional cells are expected to replace or repair damaged and missing nerve cells.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates’ unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company’s product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of thirty-eight thousand, five hundred dollars and fifty thousand Warrants/Options for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company’s technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company’s periodic reports, including forms filed with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.

SOURCE Crystal Research Associates, LLC


Source: newswire